Oxford University Press

SHERPA: Yellow

People

  1. Postow
    Postow
  2. Chaft
    Chaft
  3. Rudin
    Rudin
  4. Segal
    Segal
  5. Shoushtari
    Shoushtari
  6. Brady
    Brady
  7. Coit
    Coit
  8. Fish
    Fish
  9. Friedman
    Friedman
  10. Gordon
    Gordon

Groups

  1. Department of Medicine (38)
  2. GSK Faculty (38)
  3. Melanoma and Immunotherapeutics Service (38)
  4. Solid Tumor Oncology Division (38)
  5. Melanoma Disease Management Team (6)
  6. Thoracic Oncology (5)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  8. Hematologic Malignancies, Division of (3)
  9. Nursing (3)
  10. Advanced Practice Providers (2)
Search Within
  1. "Jedd Wolchok"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (11)
Groups
  1. Department of Medicine (38)
  2. GSK Faculty (38)
  3. Melanoma and Immunotherapeutics Service (38)
  4. Solid Tumor Oncology Division (38)
  5. Melanoma Disease Management Team (6)
  6. Thoracic Oncology (5)

More Groups

People
  1. Jedd Wolchok (38)
  2. Matthew Hellmann (5)
  3. Michael Postow (4)
  4. Jamie Chaft (3)
  5. Margaret Callahan (3)
  6. Alexander Shoushtari (2)

More People

Years
  1. 2021 (1)
  2. 2020 (3)
  3. 2019 (2)
  4. 2018 (3)
  5. 2017 (5)
  6. 2016 (6)

More Years

Publications
  1. Annals of Oncology (34)
  2. JNCI: Journal of the National Cancer Institute (2)
  3. Clinical Infectious Diseases (1)
  4. Neuro-Oncology (1)

Results (38)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
    Meeting Abstract

    Shoushtari, A. N.; Olszanski, A. J.; Nyakas, M.; Hornyak, T. J.; Wolchok, J. D.; Levitsky, V.; Møller, A. S.; Kuryk, L.; Handeland, K. R.; Jäderberg, M.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma
    Meeting Abstract

    Hamid, O.; Joshua, A. M.; Hwu, W. J.; Ribas, A.; Weber, J.; Daud, A. S.; Hodi, F. S.; Wolchok, J. D.; Mitchell, T. C.; Hersey, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO + IPI) or NIVO alone
    Meeting Abstract

    Robert, C.; Long, G. V.; Larkin, J.; Wolchok, J. D.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbé, C.; Grob, J. J.; Grossmann, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors
    Journal Article

    Chong, C. R.; Park, V. J.; Cohen, B.; Postow, M. A.; Wolchok, J. D.; Kamboj, M.
    Clinical Infectious Diseases (2020)

    Fulltext@MSK | Save
  • 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
    Meeting Abstract

    Larkin, J. M. G.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Lao, C.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    Journal Article

    Hamid, O.; Robert, C.; Daud, A.; Hodi, F. S.; Hwu, W. J.; Kefford, R.; Wolchok, J. D.; Hersey, P.; Joseph, R.; Weber, J. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Leptomeningeal melanoma metastasis presenting as intraventricular and subarachnoid hemorrhage
    Meeting Abstract

    Graham, M.; Jagannathan, R.; Rubens, E.; Wolchok, J.; Wu, S.
    Neuro-Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for quantitative immune-related pathologic response criteria (irPRC)
    Journal Article

    Cottrell, T. R.; Thompson, E. D.; Forde, P. M.; Stein, J. E.; Duffield, A. S.; Anagnostou, V.; Rekhtman, N.; Anders, R. A.; Cuda, J. D.; Illei, P. B.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Meeting Abstract

    Robert, C.; Larkin, J.; Ascierto, P. A.; Long, G. V.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbé, C.; Grob, J. J.; Grossmann, K.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save